GlobeNewswire

Statkraft inngår ny, utvidet kraftkontrakt med Boliden i Odda

Del

(Oslo/Odda, 09.09.2021) Statkraft og det svenske metallselskapet Boliden har signert en ny og utvidet kraftkontrakt som sikrer konkurransedyktig kraft til selskapets smelteverk i Odda. Kontrakten er på 1,6 TWh/år og løper i 15 år fra det nye, oppgraderte smelteverket etter planen står klart i 2024.

Boliden satser stort i Norge og fattet nylig investeringsbeslutning for å øke smeltekapasiteten i Odda fra dagens 200 000 til 350 000 tonn per år. Utvidelsen av anlegget utgjør en av de største landinvesteringene i Norge på mange år og øker det årlige kraftbehovet med 700 GWh.

- Kraftavtalen sikrer grunnlaget for produksjon av verdens mest klimaeffektive sink i Odda. Utvidelsen av virksomheten som vi nå starter på er naturligvis en viktig fremtidssatsing både for oss og samfunnet som helhet, sier Mats Gustavsson, energidirektør i Boliden.

- Vi er stolte av å sikre krafttilgangen til et oppgradert og utvidet smelteverk i Odda. Avtalen er nok et eksempel på fornyelse og utvidelse av langsiktige kraftkontrakter til norsk industri og bekrefter Statkrafts posisjon som hovedleverandør av elektrisitet til kraftkrevende industri i Norge, sier konserndirektør for Marked og IT i Statkraft, Hallvard Granheim.

Om Statkraft
Statkraft er et ledende internasjonalt selskap innen vannkraft og Europas største leverandør av fornybar energi. Konsernet produserer vannkraft, vindkraft, solkraft og gasskraft og leverer fjernvarme. Statkraft er en global markedsaktør innen energihandel og har 4 600 ansatte i 18 land.

Om Boliden
Boliden er et metallselskap med fokus på bærekraftig utvikling. Våre røtter er nordiske, markedet globalt. Kjernekompetansen er prospektering, gruver, smelteverk og metallgjenvinning. Boliden har cirka 6 000 medarbeidere og en omsetning på SEK 50 milliarder kroner. Selskapet er notert på NASDAQ OMX Stockholm.

For ytterligere informasjon, vennligst kontakt:

Lars Magnus Günther, pressetalsperson, Statkraft AS
Tel.: 00 47 91 24 16 36
E-post: lars.gunther@statkraft.com

Klas Nilsson, kommunikasjonsdirektør, Boliden
Tel.: 0046 70 453 65 88
E-post: klas.nilsson@boliden.com


Hvis du vil se dette innholdet fra www.globenewswire.com, gi ditt samtykke øverst på denne siden.
Hvis du vil se dette innholdet fra ml-eu.globenewswire.com, gi ditt samtykke øverst på denne siden.

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg pressemeldinger fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste pressemeldinger fra GlobeNewswire

After safety review The Connection study is now again open to recruit the smallest infants.22.9.2021 22:30:00 CEST | Press release

After safety review The Connection study is now again open to recruit the smallest infants. Following the completion of the DMC (Data Monitoring Committee) safety review, IBT is pleased to announce the continuation of the recruitment of patients between 500 - 1000g (Strata A and B) in the Connection study. “Given the vulnerability of the Stratum A population, infants with a birth weight less than 750 gram, we have agreed with the FDA to carefully monitor the safety of these infants. Therefore, the independent DMC has completed an additional safety review, and there are no objections to continue the study. We expect recruitment to increase as we now again recruit in two strata. ” Says Staffan Strömberg, Chief Executive Officer of IBT. About Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s Class B shares are listed on Nasdaq Stockholm, Mid-cap (IBT B). Infant Bacterial Therapeutics AB (publ) (“IBT”) is a p

Efter säkerhetsgranskning har rekryteringen av de minsta barnen i the Connection study återupptagits.22.9.2021 22:30:00 CEST | Pressemelding

Efter säkerhetsgranskning har rekryteringen av de minsta barnen i the Connection study återupptagits. Efter att säkerhetsgranskningen som utförts av Data Monitoring Committee (DMC) har slutförts kan IBT nu lämna det glädjande beskedet att rekryteringen av spädbarn i båda viktgrupperna, 500–1000 gram (Strata A och B), kan fortsätta. ”Med anledning av att spädbarnen i stratum A, som har en födelsevikt på mindre än 750 gram, är mycket känsliga har vi enats med FDA om att övervaka säkerheten för dessa spädbarn mycket noggrant. Den oberoende DMC har med anledning av detta slutfört en extra säkerhetsgranskning där det inte föreligger några invändningar mot att fortsätta studien. Vi förväntar oss att rekryteringstakten kommer att öka när vi återigen kan rekrytera i två strata. ” säger Staffan Strömberg, VD för IBT. Om Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (”IBT”) är ett publikt bolag med säte i Stockholm. Bolagets aktier av serie B handlas på Nasdaq Stockholm, Mid

Weekly share repurchase program transaction details22.9.2021 19:34:35 CEST | Press release

September 22, 2021 SBM Offshore reports the transaction details related to its EUR150 million (c. US$180 million) share repurchase program for the period September 16, 2021 through September 22, 2021. The repurchases were made under the EUR150 million share repurchase program announced on and effective from August 5, 2021. The objective of the program is to reduce share capital and, in addition, to provide shares for regular management and employee share programs. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period August 5, 2021 through September 22, 2021 can be found in the top half of the table below. Further detailed information regarding both the progress of the share repurchase program and all individual transactions can be accessed via the Investors section of the Company’s website. Share Repurchase Program Overall progress Share Repurchase Program: Total Repurchase Amount EUR 150,0

21Shares Announces Listing of Six Additional Crypto ETPs on Deutsche Boerse XETRA22.9.2021 19:11:35 CEST | Press release

Firm is first and only to give investors access to 10 crypto listings in Germany September 22, 2021 – 21Shares AG (“21Shares”), the world’s largest issuer of cryptocurrency ETPs, today announced the listing of six additional cryptocurrency ETPs for a total of 10 on Deutsche Boerse XETRA, Germany’s top trading venue for exchange traded funds. The new crypto ETPs include Solana ETP (Ticker: 21XL GY), Polkadot ETP (Ticker: PDOT GY), Cardano ETP (Ticker: DADA GY), Stellar Lumens ETP (Ticker: XLME GY), Tezos (Ticker: 21XZ GY), and the Crypto Basket Index ETP (Ticker:21XH GY). Hany Rashwan, Co-Founder and CEO of 21Shares said, “We are pleased to expand crypto investment opportunities in Germany, as one of our key markets, where we are the first and only firm providing such a comprehensive product suite. This development underscores our commitment to helping investors safely access crypto assets, now and in the future.” The six Xetra-listed crypto ETPs emphasize 21Shares’ leadership in crypto

Regarding public information about Klaipeda Prosecutor Office civil claim concerning AB “Klaipedos nafta” shares granted to employees22.9.2021 18:03:11 CEST | Press release

Public sources of information provided that the Klaipeda Prosecutor Office has submitted a civil claim against AB "Klaipedos nafta" (KN) on a ground of protection of public interest. As suggested by the media, a civil claim is concerning shares granted to employees in 2019. KN granted the shares to employees in 2019 according to the Rules for granting shares, which were approved in the general shareholders meeting. Relevant link: https://view.news.eu.nasdaq.com/view?id=b4561c449403dd0740cf7ee2c12302f9d&lang=en KN has not received a civil claim, thus is unable to provide any comments on the issue. Chief Financial Officer Mindaugas Kvekšas, +370 614 82665

Touax: H1 2021 results22.9.2021 17:45:00 CEST | Press release

PRESS RELEASE Paris, 22 September 2021 – 5.45 p.m. YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION H1 2021 results Restated revenue from activities of €52.5 million, up €1.2 millionResilient business performance with EBITDA of €21.3 million and the Group share of net income amounting to €2.0 millionFavourable outlook with strong investments Touax Group continued to deliver a positive performance while the health crisis caused further disruption. Its results were stable against the same period in 2020, with the exception of sales fees, which declined but were partially offset by sales of owned equipment. The growth in the shipping container leasing business, driven by the shortage of containers, limited asset returns and therefore sales of used containers and sales fees. ANALYSIS OF H1 2021 REVENUE FROM ACTIVITIES The restated presentation of revenue from activities is as follows: Restated Revenue from activities (in € thousand)Q1 2021Q2 2021H1 2021Q1 2020Q2 2020H1 2020

Bolder Surgical announces global launch of the CoolSeal™ Vessel Sealing Platform22.9.2021 16:44:21 CEST | Press release

CoolSeal receives CE mark, Japan PMDA approval; now available in over 20 countries worldwide LOUISVILLE, COLORADO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bolder Surgical today announced the global launch of its CoolSeal™ Vessel Sealing platform. CoolSeal has been in use since October 2020 in the U.S., and with the new international regulatory approvals the devices are available in over 20 countries around the world. Bolder Surgical provides surgeons precision electrosurgical instruments to perform minimally invasive surgery safely and effectively in pediatric and adult procedures including general, gynecological and bariatric surgical applications. The CoolSeal Vessel Sealing suite includes the 3 mm Mini (formerly JustRight Sealer) and the 5 mm Trinity Sealer/Divider/Dissector. Both devices are powered with the gold-standard efficacy of advanced bipolar RF vessel sealing technology. “Having successfully used the 3 mm vessel sealer for many cases in pediatric surgery, the Trinity 5 mm devic